Kerpener, Germany
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Phase
3Span
201 weeksSponsor
Anthos Therapeutics, Inc.Ramos Mejia
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Phase
3Span
470 weeksSponsor
Akero Therapeutics, IncRamos Mejia, Buenos Aires
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Phase
3Span
269 weeksSponsor
Akero Therapeutics, IncRamos Mejia, Buenos Aires
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Phase
1Span
338 weeksSponsor
GlaxoSmithKlineCiudadela
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Phase
3Span
205 weeksSponsor
Boehringer IngelheimCiudadela
Recruiting
1-5 of 5